A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Affiliations

• 1 Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA.
• 2 Children's Cancer Institute, School of Women's and Children's Health, UNSW, Sydney 2052, Australia.
• 3 Lowy Cancer Research Centre and the Prince of Wales Clinical School, UNSW, Sydney 2052, Australia; Centre for Health Technologies and the School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia.
• 4 RTI International, Research Triangle Park, NC 27709, USA.
• 5 Brian Michael McKeever, LLC, Lake Ronkonkoma, NY 11779, USA.
• 6 CGM Pharma, LLC, Fort Washington, PA 19034, USA.
• 7 Children's Cancer Institute, School of Women's and Children's Health, UNSW, Sydney 2052, Australia; Department of Anatomical Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
• 8 School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW 2308, Australia.
• 9 National Cancer Institute, Bethesda, MD 20892, USA.
• 10 Lowy Cancer Research Centre and the Prince of Wales Clinical School, UNSW, Sydney 2052, Australia; Department of Haematology, Prince of Wales Hospital, Sydney, NSW 2210, Australia.
• 11 Syndax Pharmaceuticals, Waltham, MA 02451, USA.
• 12 Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA. Electronic address: scott_armstrong@dfci.harvard.edu.